Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Net Income towards Common Stockholders: 2020-2023

Historic Net Income towards Common Stockholders for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$15.5 million.

  • Immuneering's Net Income towards Common Stockholders fell 15.44% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 8.03%. This contributed to the annual value of -$54.8 million for FY2023, which is 8.50% down from last year.
  • Immuneering's Net Income towards Common Stockholders amounted to -$15.5 million in Q4 2023, which was down 18.95% from -$13.1 million recorded in Q3 2023.
  • Immuneering's Net Income towards Common Stockholders' 5-year high stood at -$3.2 million during Q2 2020, with a 5-year trough of -$15.5 million in Q4 2023.
  • For the 3-year period, Immuneering's Net Income towards Common Stockholders averaged around -$11.6 million, with its median value being -$12.6 million (2022).
  • Data for Immuneering's Net Income towards Common Stockholders shows a maximum YoY tumbled of 149.56% (in 2021) over the last 5 years.
  • Quarterly analysis of 4 years shows Immuneering's Net Income towards Common Stockholders stood at -$5.8 million in 2020, then plummeted by 88.02% to -$11.0 million in 2021, then decreased by 22.75% to -$13.5 million in 2022, then dropped by 15.44% to -$15.5 million in 2023.
  • Its Net Income towards Common Stockholders stands at -$15.5 million for Q4 2023, versus -$13.1 million for Q3 2023 and -$12.3 million for Q2 2023.